148 related articles for article (PubMed ID: 33568941)
1. Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells.
Yu R; Lu Y; Yu R; Xie J; Zhou S
Cancer Manag Res; 2021; 13():953-963. PubMed ID: 33568941
[TBL] [Abstract][Full Text] [Related]
2. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S
Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919
[TBL] [Abstract][Full Text] [Related]
3. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.
Broecker-Preuss M; Becher-Boveleth N; Müller S; Mann K
Cancer Cell Int; 2016; 16():27. PubMed ID: 27042160
[TBL] [Abstract][Full Text] [Related]
4. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
5. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
6. Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma
Nayman AH; Siginc H; Zemheri E; Yencilek F; Yildirim A; Telci D
J Cancer; 2019; 10(6):1466-1478. PubMed ID: 31031856
[TBL] [Abstract][Full Text] [Related]
7. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
8. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
9. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
10. Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells.
Lee CC; Huang PY; Hsieh YH; Chen YS; Tsai JP
Tzu Chi Med J; 2022; 34(2):192-199. PubMed ID: 35465276
[TBL] [Abstract][Full Text] [Related]
11. ABT-737 potentiates cisplatin-induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway.
Zhang F; Yu X; Liu X; Zhou T; Nie T; Cheng M; Liu H; Dai M; Zhang B
Oncol Rep; 2017 Oct; 38(4):2301-2308. PubMed ID: 28849162
[TBL] [Abstract][Full Text] [Related]
12. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
13. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
[TBL] [Abstract][Full Text] [Related]
14. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Shang D; Ito N; Kamoto T; Ogawa O
Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
16. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.
Wang L; Wu H; Wang Y; Xu S; Yang C; Zhang T; Liu Y; Wang F; Chen W; Li J; Sun L
Heliyon; 2023 Aug; 9(8):e19154. PubMed ID: 37664741
[TBL] [Abstract][Full Text] [Related]
18. Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 mitogen-activated protein kinase-mediated mitochondrial and autophagic apoptosis.
Lai CP; Chen YS; Ying TH; Kao CY; Chiou HL; Kao SH; Hsieh YH
Kidney Res Clin Pract; 2023 Jul; 42(4):487-500. PubMed ID: 37165617
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
